Developing Teixobactin for Respiratory Infections
开发用于呼吸道感染的 Teixobactin
基本信息
- 批准号:10378726
- 负责人:
- 金额:$ 119.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-22 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AcuteAerosolsAmbulatory CareAnimal ModelAnimalsAntibioticsBacillus anthracisBacterial PneumoniaCOVID-19Centers for Disease Control and Prevention (U.S.)ChemicalsChronic Obstructive Pulmonary DiseaseClinicalClinical ProtocolsClinical TrialsCodeCommunicable DiseasesCommunitiesDNADevelopment PlansDoseDrug CompoundingDrug resistanceEpithelialFermentationFutureGoalsGram-Positive BacteriaHaemophilus influenzaeHospitalsHumanIn VitroInfectionInfectious Skin DiseasesInhalationIntramuscularIntravenousInvestigational DrugsInvestigational New Drug ApplicationLipid IIILipidsLiquid substanceLung infectionsMacrolide-resistanceMaximum Tolerated DoseModelingMoraxella catarrhalisMorbidity - disease rateMusMycobacterium tuberculosisNebulizerPamphletsPatientsPeptidoglycanPharmaceutical PreparationsPharmacologyPharmacology and ToxicologyPlasmaPneumoniaPredispositionProductionPropertyRattusReportingResearchResearch PersonnelResistanceResistance profileRespiratory Tract InfectionsRouteSafetySepsisSkinStaphylococcus aureusStreptococcus pneumoniaeStructureTeichoic AcidsTest ResultTestingTherapeuticThigh structureToxicologyVentilatorbactericidebaseco-infectioncostimprovedin vitro testingin vivomeetingsmethicillin resistant Staphylococcus aureusmicrobialmortalitymouse modelmutantpathogenpharmacokinetics and pharmacodynamicspneumonia modelpreclinical developmentpredictive modelingresistance frequencyrespiratoryrespiratory pathogenside effect
项目摘要
ABSTRACT: The major goal of this proposal is to investigate the potential for teixobactin, our newly discovered
antibiotic, to treat respiratory infections. As reported in 2019 by the CDC, pneumonia caused by drug resistant
Streptococcus pneumoniae, as well as methicillin-resistant Staphylococcus aureus (MRSA), are considered
serious threats. In addition, respiratory bacterial co-infections with Covid-19 have recently been recognized as a
significant problem. Haemophilus influenzae and Moraxella catarrhalis are two other respiratory pathogens
particularly problematic in patients with chronic obstructive pulmonary disease and are common causes of
community-acquired bacterial pneumonia (CABP).
The most remarkable, and unexpected property of teixobactin is the lack of any detectable resistance to
this compound. Teixobactin hits two related targets—lipid II, precursor of peptidoglycan and lipid III, precursor of
wall teichoic acid. These highly conserved targets are not mutable—they are not proteins and are not directly
coded by DNA. Since our discovery of teixobactin, we and others have failed to generate resistant mutants in
any species including S. aureus, Mycobacterium tuberculosis or Bacillus anthracis. Teixobactin is highly
efficacious in animal models of thigh, lung and blood infections. Animal infection models predict that the human
dose of teixobactin for acute skin and skin structure infections (ABSSSI) will be very low (≤1 mg/kg/day), which
is advantageous, as a low dose may minimize side effects and reduce manufacturing costs.
Teixobactin is in preclinical development as an intravenous (IV) drug for treating skin infections caused
by pathogens such as MRSA. A pre-Investigational New Drug (IND) meeting with FDA was held in December
2018 whereby the FDA generally agreed with our development plan. An IND submission for ABSSSI is planned
for 2022.
In this project, Aim 1 will produce enough teixobactin for all the proposed studies. Aim 2 will conduct
efficacy and PK/PD studies in animal models of pneumonia. Aim 3 will test in vitro susceptibility, bactericidal
activity, post antibiotic effect (PAE) and resistance in recent clinical isolates from respiratory infections. Aim 4
will prepare and submit an IND application for intravenous treatment of a respiratory infection. Aim 5 will explore
alternative routes of TXB administration (inhalation and intramuscular delivery), which would be particularly
useful for outpatient treatment of respiratory and other infections. With successful completion of these projects,
we will have demonstrated the promise of teixobactin for treating drug resistant respiratory infections and
explored more convenient routes of TXB administration.
摘要:本研究的主要目的是研究新发现的teixobactin的潜力
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dallas Hughes其他文献
Dallas Hughes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dallas Hughes', 18)}}的其他基金
Teixobactin Development for Tuberculosis
Teixobactin 治疗结核病的开发
- 批准号:
10546221 - 财政年份:2022
- 资助金额:
$ 119.51万 - 项目类别:
Developing Teixobactin for Respiratory Infections
开发用于呼吸道感染的 Teixobactin
- 批准号:
10201364 - 财政年份:2021
- 资助金额:
$ 119.51万 - 项目类别:
Developing Teixobactin for Respiratory Infections
开发用于呼吸道感染的 Teixobactin
- 批准号:
10552672 - 财政年份:2021
- 资助金额:
$ 119.51万 - 项目类别:
Preclinical development of teixobactin, a new antibiotic
新型抗生素teixobactin的临床前开发
- 批准号:
8903692 - 财政年份:2015
- 资助金额:
$ 119.51万 - 项目类别:
Preclinical development of teixobactin, a new antibiotic
新型抗生素teixobactin的临床前开发
- 批准号:
9000621 - 财政年份:2015
- 资助金额:
$ 119.51万 - 项目类别:
Selective agents against C. difficile infection
针对艰难梭菌感染的选择性药物
- 批准号:
8842587 - 财政年份:2014
- 资助金额:
$ 119.51万 - 项目类别:
相似海外基金
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
- 批准号:
10092043 - 财政年份:2024
- 资助金额:
$ 119.51万 - 项目类别:
EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
- 批准号:
2332007 - 财政年份:2024
- 资助金额:
$ 119.51万 - 项目类别:
Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000021/1 - 财政年份:2024
- 资助金额:
$ 119.51万 - 项目类别:
Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000358/1 - 财政年份:2024
- 资助金额:
$ 119.51万 - 项目类别:
Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
- 批准号:
DP240100389 - 财政年份:2024
- 资助金额:
$ 119.51万 - 项目类别:
Discovery Projects
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
- 批准号:
83001507 - 财政年份:2023
- 资助金额:
$ 119.51万 - 项目类别:
Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
- 批准号:
ST/X001091/1 - 财政年份:2023
- 资助金额:
$ 119.51万 - 项目类别:
Research Grant
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
- 批准号:
2326096 - 财政年份:2023
- 资助金额:
$ 119.51万 - 项目类别:
Standard Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
- 批准号:
10080253 - 财政年份:2023
- 资助金额:
$ 119.51万 - 项目类别:
Small Business Research Initiative














{{item.name}}会员




